Becton DickinsonBDX +2.44%76 Gross Margin % is 45.69% as of Mar. 2026, which is 1% above its 10-year median of 45.33. GuruFocus rates BDX with a GF Score™ of 76/100 and a GF Value™ of $191.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Becton Dickinson ranks worse than 57.76% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Becton Dickinson had a gross margin of 45.69% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Becton Dickinson Gross Margin % Related Terms
Becton Dickinson Gross Margin % Historical Data
* Premium members only.
The historical data trend for Becton Dickinson's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Becton Dickinson's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Becton Dickinson Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Becton Dickinson's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Becton Dickinson's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Becton Dickinson (BDX) has a Gross Margin % of 45.69% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Becton Dickinson and its competitors. This is near median its historical median of 45.33. Over the past decade, Becton Dickinson's Gross Margin % has ranged from 42.17 to 49.33. According to the industry distribution chart, Becton Dickinson ranks #465 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 57.8%.
Is Becton Dickinson's Gross Margin % too high?
Becton Dickinson's current Gross Margin % of 45.69% is near median its 10-year median of 45.33. Over the past 10 years, this metric has ranged from a low of 42.17 to a high of 49.33. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Becton Dickinson's value of 45.69% is 12.3% below this industry median. Based on the distribution chart, Becton Dickinson ranks #465 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Becton Dickinson has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Becton Dickinson's Gross Margin % compare to MDLN and RMD?
According to the Medical Devices & Instruments industry distribution chart, Becton Dickinson ranks #465 out of 805 companies for Gross Margin %. This places Becton Dickinson in the lower half of its industry. The industry median Gross Margin % is 52.07. Becton Dickinson's value of 45.69% is 12.3% below this benchmark. Historically, Becton Dickinson's own Gross Margin % has ranged from 42.17 to 49.33 over the past decade. While the company's 10-year median is 45.33 vs. the industry median of 52.07, Becton Dickinson has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Becton Dickinson's current Gross Margin % of 45.69% is 12.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Becton Dickinson and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Becton Dickinson's current Gross Margin % is 45.69%, which is near median its own 10-year median of 45.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Becton Dickinson stock overvalued right now?
Based on GuruFocus' analysis, Becton Dickinson (BDX) is currently considered Modestly Undervalued. The stock's GF Value™ is $191.05, compared to a current price of $151.38 — trading 20.8% below its estimated fair value. The current Gross Margin % is 45.69%, which is near median its 10-year median of 45.33 and 12.3% below the Medical Devices & Instruments industry median of 52.07. Becton Dickinson's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Becton Dickinson (BDX), the current Gross Margin % is 45.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Becton Dickinson (BDX) Overvalued in 2026?
Based on GuruFocus' analysis, Becton Dickinson stock appears to be undervalued.
The current stock price of $151.38 is trading 20.8% below its estimated GF Value™ of $191.05.
GuruFocus considers Becton Dickinson to be Modestly Undervalued.
Key valuation signals for BDX:
Gross Margin %: 45.69% (near median its 10-year median of 45.33)
GF Value™: $191.05 vs. price of $151.38 (20.8% below fair value)
Industry Position: 12.3% below the Medical Devices & Instruments median (#465 of 805)
No single metric tells the full story. See the BDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
76GF Score
Get the complete analysis for BDX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDX has been successfully added to your 
